Skip to main content

Table 8 Basecase results

From: Cost effectiveness of vildagliptin versus glimepiride as add-on treatment to metformin for the treatment of diabetes mellitus type 2 patients in Greece

 

Strategy 1

Strategy 2

Difference (strategy 1 vs. strategy 2)

Total costs

€10,003

€10,077

−€74

QALYs

6.30

6.19

0.11

Life years

8.07

7.96

0.11

ICER (cost per QALY gained)

  

Dominant

ICER (cost per LY gained)

  

Dominant

Back to article page

Cost Effectiveness and Resource Allocation

ISSN: 1478-7547

Contact us